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ABSTRACT Of 1,493 encounters of males at a sexually transmitted infection (STI) clinic
in a community with a high prevalence of STI, Chlamydia trachomatis was detected in
8.7% and Neisseria gonorrhoeae was detected in 6.6%. Additional Trichomonas vaginalis
and Mycoplasma genitalium screening found 17.4% and 23.9% of the encounters, re-
spectively, to be positive for STI. STI agents were detected in 13.7% of urine specimens;
addition of pharyngeal and rectal collections to the analysis resulted in detection of STI
agents in 19.0% and 23.9% of encounters, respectively. A total of 101 (23.8%) encoun-
ters of identiﬁed STI involved sole detection of M. genitalium. Expansion of the STI ana-
lyte panel (including M. genitalium) and additional specimen source sampling within a
comprehensive STI screening program increase identiﬁcation of male STI carriers.
KEYWORDS Mycoplasma genitalium, transcription-mediated ampliﬁcation,
Trichomonas vaginalis
Extraurogenital screening for agents of sexually transmitted infection (STI) has beenadvocated in a number of clinical and public health scenarios (1). Studies have
reported increased rates of Chlamydia trachomatis and Neisseria gonorrhoeae detection
from pharyngeal and rectal specimens via nucleic acid ampliﬁcation testing compared
to rates found with culture (2–7). Moreover, differences in clinical and in vitro detection
rates yielded by transcription-mediated ampliﬁcation (TMA) versus DNA ampliﬁcation
modalities have been demonstrated (4–9), likely owing to target capture-based removal
of endogenous inhibitors (10, 11). Detection of Trichomonas vaginalis RNA from pha-
ryngeal specimens (12) and Mycoplasma genitalium RNA from urine specimens (13) of
male STI clinic attendees has recently been reported on the basis of commercial TMA
assays. The purpose of this investigation was to assess both the capacity of TMA for
detection of M. genitalium from pharyngeal and rectal specimens and the potential for
multispecimen analysis in the overall identiﬁcation of male carriers of STI agents.
(Results of this work were presented in part at ASM Microbe, Boston, MA, 16 to 20
June 2016.)
With an Institutional Review Board-approved protocol, screening practices for male
attendees of a Milwaukee, WI, STI clinic were audited from March 2014 through
December 2015. The high-STI-prevalence nature of this community was noted previ-
ously (14). Aliquots of ﬁrst-void urine were dispensed into Aptima urine specimen
transport tubes (Hologic, San Diego, CA). Pharyngeal and rectal swab specimens were
obtained using the Aptima unisex swab specimen collection kit (Hologic).
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C. trachomatis- and N. gonorrhoeae-speciﬁc analyses from all collections were per-
formed with the Aptima Combo 2 assay (Hologic), including laboratory-validated
assessments of pharyngeal and rectal specimens. T. vaginalis detection occurred via an
Aptima Trichomonas vaginalis assay (Hologic) that was laboratory validated for analysis
of male urine and pharyngeal specimens. Detection of M. genitalium occurred via
TMA-based analyte-speciﬁc reagent (ASR) (Hologic). All assays were performed on Tigris
DTS (Hologic). M. genitalium ASR relative light unit output of 50,000 signiﬁed a
positive result. The signiﬁcance test of proportions was used to determine whether
changes in detection rates were signiﬁcant.
Collection of one and two specimens was used to manage 4.4% and 41.3% of patient
encounters, respectively (Fig. 1). The two most commonly detected STI agents from
pharyngeal collections were N. gonorrhoeae (3.3%) and T. vaginalis (1.5%) (Fig. 2). M.
genitalium was detected from 0.9% of pharyngeal specimens. Detection rates of M. geni-
talium (5.8%), C. trachomatis (6.0%), and N. gonorrhoeae (6.4%) from rectal specimens were
generally similar to those of M. genitalium (6.6%) and C. trachomatis (5.1%) from urine
specimens (Fig. 2). Analysis of rectal specimens for T. vaginalis was not attempted because
previous data demonstrated 0% prevalence in this population from this specimen source (12).
Traditional molecular STI assays have targeted C. trachomatis and N. gonorrhoeae.
TMA-based detection of other STI agents has been documented from male urogenital
(T. vaginalis, M. genitalium) and pharyngeal (T. vaginalis) specimens (12, 13, 15, 16). C.
trachomatis and N. gonorrhoeae screening from both urine and extraurogenital sources
in this study resulted in 228 instances of STI (15.3% incidence rate) (Fig. 3). Addition of
T. vaginalis and M. genitalium analytes into the comprehensive screen increased
incidence rates to 17.4% (P  0.11 versus C. trachomatis and N. gonorrhoeae screening)
and 23.9% (P 0.0002 versus combined C. trachomatis, N. gonorrhoeae, and T. vaginalis
screening), respectively.
A total of 1,493 clinic encounters resulted in the collection of 1,465 urine specimens,
1,443 pharyngeal specimens, and 823 rectal specimens. This numeric rank formulated the
basis of the sequential order of the analysis presented in Fig. 4. Screening only urine for all
four analytes resulted in 205 (13.7%) instances of STI diagnosis (Fig. 4). This value increased
FIG 1 Screening of 1,493 men from a Milwaukee, WI, STI clinic, delineated by permutations of urine, pharyngeal,
and rectal specimen collection.
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to 284 patient encounters by addition of pharyngeal screening (P  0.0002). Addition of
rectal screening accounted for the remainder of the 357 instances of STI diagnosis in this
cohort (P  0.001 versus combined urine and pharyngeal screening). Of the 205 instances
of STI diagnosis via urine screening, sole M. genitalium detection was observed in 73
encounters (4.9% of all clinic encounters) (Fig. 4); addition of pharyngeal and rectal
FIG 2 Transcription-mediated ampliﬁcation detection rates of Chlamydia trachomatis, Neisseria gonor-
rhoeae, Trichomonas vaginalis, and Mycoplasma genitalium in 1,465 urine, 1,443 pharyngeal, and 823
rectal specimens. †, P  0.0002 versus detection of other etiologies; ‡, P  0.002; *, not tested.
FIG 3 Cumulative STI incidence rate, as a function of additional transcription-mediated ampliﬁcation
assays. †, P  0.0002 versus combined Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas
vaginalis screening.
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screening increased sole M. genitalium detection rates to 5.3% and 6.8% (P  0.03),
respectively, of all clinic visits. In total, sole detection of M. genitalium contributed to 23.8%
of encounters that yielded at least one STI.
Among Centers for Disease Control and Prevention recommendations for STI man-
agement of sexually active men who have sex with men (MSM) is an annual test for
rectal infection with C. trachomatis and N. gonorrhoeae in those who have experienced
receptive anal intercourse during the previous 12 months (1). Pharyngeal testing for N.
gonorrhoeae should be performed in MSM who have received oral intercourse during
that interval. Although pharyngeal C. trachomatis screening is not a recommendation,
studies have described a propensity of pharyngeal C. trachomatis carriage to result in
disease transmission to genital sites (17, 18). More-frequent screening may be indicated
per additional sexual risk factors.
Perhaps as a result of these updated guidelines, the percentage of encounters
resulting in multiple specimen collections in this study (95.6%) exceeded that from one
previous survey of this STI clinic population (64.2%) (12). Not only did multisource
sampling and multianalyte testing in an STI clinic population provide general beneﬁt,
a rather high-risk, susceptible population may also be appreciated when analyzing the
demographics characterized by extraurogenital M. genitalium carriage. The median
ages of attendees with detectable pharyngeal and rectal M. genitalium were 24.0 and
24.5 years, respectively. Men with detectable pharyngeal and rectal M. genitalium
averaged 10.4 and 7.2 sexual partners, respectively, over the previous 12 months.
Moreover, 93.3% and 81.8% of men with detectable rectal and pharyngeal M. genita-
lium, respectively, engaged in homosexual practices.
M. genitalium detection in pharyngeal and rectal specimens was conﬁrmed by
positive results generated by repeat M. genitalium ASR from 92.3% and 91.5% of
specimens, respectively. Previous data revealed that repeat TMA analysis performed the
same as alternative target testing for conﬁrmation of STI agent detection (19, 20). In
general, speciﬁcity of M. genitalium ASR within a female acute and subacute population
was demonstrated by 98.8% concordance between results from M. genitalium ASR and
alternative target testing (21).
FIG 4 Cumulative STI (open bars) and Mycoplasma genitalium (solid bars) incidence rates, as function of
additional specimen source analysis. *, P  0.001 versus single- or double-collection paradigms; †, P 
0.02 versus urine M. genitalium screening.
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In conclusion, procurement of rectal, pharyngeal, and urine specimens increases
overall identiﬁcation of male STI carrier status. Moreover, the advent of commercial M.
genitalium ASR may result in a substantial percentage of sole M. genitalium detection
within this demographic. Additional studies are warranted to determine ﬁnancial and
disease transmission impacts relative to routine incorporation of this assay into a
comprehensive STI screening algorithm.
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